BioSpace News Archive

As part of its continued global expansion, Glooko, the leader in diabetes digital health and data management solutions, today announced the appointment of Zach Henderson as Chief Commercial Officer and Komathi Stem as Chief Operating Officer

New team members add decades of healthcare and health insurance cost containment expertise to industry leader

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, announced updated results from its Phase 1b/2 clinical trial of ciforadenant, an adenosine A2A receptor antagonist, in patients with metastatic castration resistant prostate cancer (mCRPC).

iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the fourth quarter and year ended December 31, 2019, before the market open, and host a conference call at 4:30pm Eastern Time on Thursday, February 27, 2020.

While 65% say they don’t have access to a COVID-19 test kit, only 9% are very concerned; verbatim remarks citing media hype, emphasize the greater concern is flu

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announced updated results from the combination arm of KEYNOTE-46 (Part B), the Company’s ongoing Phase 1/2 study investigating ADXS-PSA with KEYTRUDA® (pembrolizumab) in patients with metastatic, castrate-resistant prostate cancer (mCRPC) at the ASCO Genitourinary Cancers Symposium in San Francisco, California.

Thermo Fisher Scientific and NanoPin Technologies, Inc. have entered into a collaborative relationship to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry -based workflows.

Trovagene, Inc. (Nasdaq: TROV), today announced positive data from its ongoing Phase 2 trial of onvansertib in combination with Zytiga® (abiraterone – Johnson & Johnson)/prednisone, all administered orally, for the treatment of patients with Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC)

Decision Resources Group, www.decisionresourcesgroup.com, a premier provider of high-value healthcare data, analytics, and insights products and services to the healthcare industry, has been named as the new partner for the Health Industry Distributors Association industry data program.

77% of all participating patients who are typically considered ineligible have received a bone marrow transplant in the SIERRA trial, the only randomized Phase 3 trial to offer potentially curative allogeneic transplant to older patients with active, relapsed or refractory AML